Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $55.00

Shares of Sanofi (NASDAQ:SNY) have earned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $55.00.

A number of brokerages recently issued reports on SNY. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley began coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective on the stock.

Sanofi Trading Down 1.6 %

Sanofi stock opened at $45.39 on Tuesday. Sanofi has a 52-week low of $42.63 and a 52-week high of $57.82. The company has a market cap of $114.82 billion, a P/E ratio of 19.23, a P/E/G ratio of 1.71 and a beta of 0.61. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The business has a 50-day simple moving average of $47.52 and a two-hundred day simple moving average of $48.67.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The business had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. Analysts predict that Sanofi will post 4.16 EPS for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a $1.478 dividend. This represents a yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is presently 58.47%.

Hedge Funds Weigh In On Sanofi

Several hedge funds have recently modified their holdings of the stock. Cardinal Capital Management raised its holdings in shares of Sanofi by 0.3% during the 4th quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock worth $2,927,000 after acquiring an additional 201 shares in the last quarter. Daiwa Securities Group Inc. increased its stake in Sanofi by 3.4% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock worth $325,000 after acquiring an additional 216 shares during the last quarter. Wynn Capital LLC increased its stake in Sanofi by 4.5% during the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after acquiring an additional 226 shares during the last quarter. Sage Rhino Capital LLC raised its position in Sanofi by 2.8% during the third quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock valued at $468,000 after purchasing an additional 240 shares during the period. Finally, Angeles Investment Advisors LLC lifted its stake in shares of Sanofi by 2.1% in the 4th quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock valued at $598,000 after purchasing an additional 244 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.